| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | 1 | Y | 1 Delayed V-O | 247 | 68 | 16 | 6 | 4 | 2 | 0 | 03/02/2021 | 277 | 96 |
| 2 Early V-O | 132 | 31 | 21 | 15 | 8 | 2 | ||||||||
| 200 | 47 | 27 | 19 | 10 | 2 | |||||||||
| 21CTP.LEUK01-ALL, Ph+, Asciminib, Dasatinib and Prednisone | 1 | Y | 1 Asciminib+Dasatinib+PRED / Blinatumomab+Dasatinib | 55 | 4 | 4 | 4 | 4 | 3 | 1 | 04/13/2026 | |||
| 4 | 4 | 4 | 4 | 3 | 1 | |||||||||
| MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena | 1 | Y | 1 ASTX727 + Venetoclax + Enasidenib (Safety Run-in) | 102 | 8 | 6 | 0 | 0 | 0 | 0 | 05/16/2025 | 237 | 64 | |
| 2 ASTX727 + Venetoclax | 7 | 7 | 7 | 7 | 3 | 0 | ||||||||
| 3 ASTX727 + Venetoclax + Enasidenib | 5 | 5 | 5 | 5 | 2 | 0 | ||||||||
| 20 | 18 | 12 | 12 | 5 | 0 | |||||||||
| MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental | 1 | Y | 1 Daunorubicin + Cytarabine | 335 | 15 | 10 | 4 | 2 | 0 | 0 | 09/25/2024 | 298 | 107 | |
| 2 Venetoclax + Daunorubicin + Cytarabine | 16 | 11 | 6 | 3 | 0 | 0 | ||||||||
| 3 Venetoclax + Azacitidine | 16 | 11 | 4 | 2 | 1 | 0 | ||||||||
| 4 (Daunorubicin + Cytarabine) Liposome | 15 | 10 | 3 | 0 | 0 | 0 | ||||||||
| 5 (Daunorubicin + Cytarabine) Liposome + Venetoclax | 16 | 11 | 8 | 4 | 1 | 0 | ||||||||
| 78 | 53 | 25 | 11 | 2 | 0 | |||||||||
| MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials | 1 | Y | 1 Screening | 1177 | 614 | 307 | 148 | 41 | 4 | 06/18/2024 | 367 | 140 | ||
| 1177 | 614 | 307 | 148 | 41 | 4 | |||||||||
| 2 | Y | 2 Re-screening | 147 | 99 | 70 | 27 | 7 | 0 | 06/18/2024 | |||||
| 147 | 99 | 70 | 27 | 7 | 0 | |||||||||
| 3 | Y | 3 Re-screening | 49 | 42 | 29 | 14 | 6 | 0 | 06/18/2024 | |||||
| 49 | 42 | 29 | 14 | 6 | 0 | |||||||||
| 4 | Y | 4 Re-screening | 7 | 6 | 5 | 5 | 1 | 0 | 06/18/2024 | |||||
| 7 | 6 | 5 | 5 | 1 | 0 | |||||||||
| Yes | EA9213-T-ALL, dara-hyal for chemo refractory MRD | 0 | E | Total Registrations | 9 | 3 | 3 | 1 | 0 | 0 | 02/24/2023 | 112 | 38 | |
| 9 | 3 | 3 | 1 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 4 | 1 | 1 | 1 | 0 | 0 | 02/24/2023 | |||||
| 4 | 1 | 1 | 1 | 0 | 0 | |||||||||
| No | A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | 0 | E | Total Registrations | 73 | 2 | 2 | 0 | 0 | 0 | 11/09/2018 | 291 | 87 | |
| 73 | 2 | 2 | 0 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 58 | 1 | 1 | 0 | 0 | 0 | 11/09/2018 | |||||
| 58 | 1 | 1 | 0 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 44 | 0 | 0 | 0 | 0 | 0 | 11/09/2018 | |||||
| 44 | 0 | 0 | 0 | 0 | 0 | |||||||||
| A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat | 0 | E | Total Registrations | 12 | 1 | 1 | 0 | 0 | 0 | 08/13/2020 | 166 | 46 | ||
| 12 | 1 | 1 | 0 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 6 | 1 | 1 | 1 | 0 | 0 | 08/13/2020 | |||||
| 6 | 1 | 1 | 1 | 0 | 0 | |||||||||
| MM1OA-EA02-MyeloMATCH: AML, New Dx, Ven+HMA | 1 | E | Total Registrations | 19 | 15 | 5 | 2 | 1 | 0 | 12/02/2024 | 300 | 103 | ||
| 19 | 15 | 5 | 2 | 1 | 0 | |||||||||
| MM1YA-CTG01-MyeloMATCH: AML, New Dx w/ Int Risk, Ven+Chem | 1 | E | Total Registrations | 12 | 8 | 6 | 4 | 2 | 0 | 10/14/2024 | 59 | 12 | ||
| 12 | 8 | 6 | 4 | 2 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| S2504 Richter Trans., Untreated, R-CHOP +/- Pirto | 1 Registration | 01-Jun-26 | 6 | 3 |
| 21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone | 2 Post-Remission | 15-May-25 | ||
| 3 Maintenance | 15-May-25 |